STELARA: payments to doctors
Payments that named STELARA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $29.6M
- Providers
- 41,588
- Transactions
- 441,909
- Average per transaction
- $67
The per-transaction average — $67 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 41,588 providers the average total is $713, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $17,721,584 | 59.8% |
| Janssen Scientific Affairs, LLC | $11,136,174 | 37.6% |
| Janssen Research & Development, LLC | $710,298 | 2.4% |
| Janssen Global Services, LLC | $64,461 | 0.2% |
| Medical Device Business Services, Inc. | $29 | 0.0% |